[go: up one dir, main page]

WO1997039759A3 - Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder - Google Patents

Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder Download PDF

Info

Publication number
WO1997039759A3
WO1997039759A3 PCT/US1997/006712 US9706712W WO9739759A3 WO 1997039759 A3 WO1997039759 A3 WO 1997039759A3 US 9706712 W US9706712 W US 9706712W WO 9739759 A3 WO9739759 A3 WO 9739759A3
Authority
WO
WIPO (PCT)
Prior art keywords
omega
bipolar disorder
treatment
fatty acids
phosphatidylcholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/006712
Other languages
French (fr)
Other versions
WO1997039759A2 (en
Inventor
Andrew L Stoll
Wolfram E Severus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to US09/269,361 priority Critical patent/US6344482B1/en
Priority to AU27384/97A priority patent/AU2738497A/en
Publication of WO1997039759A2 publication Critical patent/WO1997039759A2/en
Publication of WO1997039759A3 publication Critical patent/WO1997039759A3/en
Anticipated expiration legal-status Critical
Priority to US10/068,035 priority patent/US20020091103A1/en
Priority to US11/052,533 priority patent/US20050267212A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to a method of treating patients with bipolar disorder by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g. a triacylglycerol, which releases free fatty acid after ingestion by a patient. The present invention is also directed to triacylglycerols which are esterified at the gamma carbon of glycerol to phosphocholine and at either the alpha or beta carbon of glycerol to an omega-3 fatty acid. These 'omega-3 phosphatidylcholines' are also used in the treatment of patients with bipolar disorder.
PCT/US1997/006712 1996-04-24 1997-04-23 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder Ceased WO1997039759A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/269,361 US6344482B1 (en) 1997-04-23 1997-04-23 Omega-3 fatty acids in the treatment of bipolar disorder
AU27384/97A AU2738497A (en) 1996-04-24 1997-04-23 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US10/068,035 US20020091103A1 (en) 1997-04-23 2002-02-05 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US11/052,533 US20050267212A1 (en) 1997-04-23 2005-02-07 Omega-3 fatty acids in the treatment of depression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1614096P 1996-04-24 1996-04-24
US60/016,140 1996-04-24

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09/269,361 A-371-Of-International US6344482B1 (en) 1997-04-23 1997-04-23 Omega-3 fatty acids in the treatment of bipolar disorder
US09269361 A-371-Of-International 1997-04-23
US10/068,035 Continuation US20020091103A1 (en) 1997-04-23 2002-02-05 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US10/083,913 Continuation-In-Part US6852870B2 (en) 1997-04-23 2002-02-27 Omega-3 fatty acids in the treatment of depression

Publications (2)

Publication Number Publication Date
WO1997039759A2 WO1997039759A2 (en) 1997-10-30
WO1997039759A3 true WO1997039759A3 (en) 1998-01-15

Family

ID=21775605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006712 Ceased WO1997039759A2 (en) 1996-04-24 1997-04-23 Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder

Country Status (2)

Country Link
AU (1) AU2738497A (en)
WO (1) WO1997039759A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691871B2 (en) 2009-04-29 2014-04-08 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9138415B2 (en) 2009-04-29 2015-09-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852870B2 (en) * 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
ES2288193T3 (en) 2001-07-27 2008-01-01 NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. NATURAL PHOSPHOLIPIDS OF MARINE ORIGIN CONTAINING FLAVONOIDS AND POLYINSATURATED PHOSPHOLIPIDS AND ITS USES.
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US20140343143A1 (en) * 2004-01-21 2014-11-20 Tiberio Bruzzese Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2219652B1 (en) * 2007-11-16 2012-04-25 Baylor College Of Medicine Phospholipid compositions and uses thereof
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
EP2596786B1 (en) 2009-02-10 2019-11-27 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
KR101788342B1 (en) 2009-10-29 2017-10-19 아카스티 파마, 인크. Concentrated therapeutic phospholipid compositions
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2949344A3 (en) * 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
KR102153245B1 (en) 2012-01-06 2020-09-08 옴테라 파마슈티칼스, 인크. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
UA128280C2 (en) 2012-06-29 2024-05-29 Амарін Фармасьютікалз Айрленд Лімітед METHOD OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT RECEIVING STATIN THERAPY
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
KR102079747B1 (en) 2015-02-11 2020-02-20 에이커 바이오마린 앤탁틱 에이에스 Lipid composition
EP3256003B2 (en) 2015-02-11 2025-07-16 Aker Biomarine Antarctic AS Lipid extraction processes
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
LT4056176T (en) 2018-09-24 2024-08-12 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
JP2022554020A (en) 2019-11-12 2022-12-27 アマリン ファーマシューティカルズ アイルランド リミテッド Methods of reducing the risk of cardiovascular events in subjects with atrial fibrillation and/or atrial flutter
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289204A2 (en) * 1987-04-27 1988-11-02 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
WO1994028913A1 (en) * 1993-06-09 1994-12-22 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289204A2 (en) * 1987-04-27 1988-11-02 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
WO1994028913A1 (en) * 1993-06-09 1994-12-22 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9034388B2 (en) 2007-03-28 2015-05-19 Aker Biomarine Antartic As Bioeffective krill oil compositions
US9078905B2 (en) 2007-03-28 2015-07-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9320765B2 (en) 2007-03-28 2016-04-26 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9375453B2 (en) 2007-03-28 2016-06-28 Aker Biomarine Antarctic As Methods for producing bioeffective krill oil compositions
US8691871B2 (en) 2009-04-29 2014-04-08 Amarin Pharmaceuticals Ireland Limited Methods of treating mixed dyslipidemia
US9138415B2 (en) 2009-04-29 2015-09-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Also Published As

Publication number Publication date
WO1997039759A2 (en) 1997-10-30
AU2738497A (en) 1997-11-12

Similar Documents

Publication Publication Date Title
WO1997039759A3 (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
WO2003072111A3 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
KR100657642B1 (en) Oil comprising eicosapentaenoic acid and/or stearidonic acid
CA2033823C (en) Combination of gla or dgla and selenium in psychiatric disorder treatment
DE60000133D1 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
GB2229363B (en) Eicosapentaenoic acid
IE59445B1 (en) Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
ATE227520T1 (en) NUTRITIONAL COMPOSITION
IL137848A0 (en) Indole-3-propionic acids, salts and esters thereof used as medicaments
WO1993006812A3 (en) Use of an emulsion to prepare an intravenously administered medicament for treating skin diseases
DE3570362D1 (en) Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
KR970704433A (en) Use of DHA as a pharmaceutical composition (Use of DHA as a pharmaceutical composition)
CS545686A1 (en) Farmaceuticky prostredek a antihepatotoxickym pusobenim
DK0507851T3 (en) Quinolone-matalion acid complexes
PT79648B (en) PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH SPECIAL 1,2-DIACYL-GLYCERO-3-PHOSPHOCHOLINES FOR THE TREATMENT OF DISEASES IN THE STOMACH-DARM AREA
DE3781686D1 (en) COMPOSITION CONTAINING FATTY ACID AND CYCLOSPORINE WITH REDUCED NEPHROTOXICITY.
Guillot et al. Intestinal absorption of medium chain fatty acids: in vivo studies in pigs devoid of exocrine pancreatic secretion
JP2002524417A5 (en)
CA2052577A1 (en) Therapeutic uses of eicosapentaenoic acid
RU98102466A (en) METHOD FOR TREATING PATIENTS WITH OSTEOARTHROSIS
Klauda et al. 2‐Monoglyceride as an aid to the absorption of cholesterol into the thoracic lymph
IT1238210B (en) Cefamandol naftate esters, preparation procedure and relative pharmaceutical compositions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97538281

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09269361

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase